EGFRvIII-specific CAR T-cells (YooYoung Pharmaceuticals)

N/A

Report date: 2025/03/20 14:58:36

Base Information

Drug NameEGFRvIII-specific CAR T-cells (YooYoung Pharmaceuticals)
Drug Alias Nameanti-EGFRvIII CAR T-cell therapy (YooYoung Pharmaceutical)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesYooYoung Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYooYoung Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A